TOP 1902- GRID- Advanced NSCLC - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the study drug (GT-103) and to find the best dose to give to patients with advanced NSCLC.

What is the Condition Being Studied?

Advanced Stage Non-Small Cell Lung Cancer

Who Can Participate in the Study?

-Adults 18+
-Have a diagnosis of advanced non-small cell lung cancer

For more information on who can participate in this study please contact the study team.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Have a physical exam
-Have blood samples taken
-Get the study drug (GT-103) every 3 weeks as long as you continue to do well and tolerate the drug. The study drug will be given into your arm by an IV.

Once you complete your treatment, you will complete a follow-up phone call every 12 weeks for up to 3 years.

Study Details

Full Title
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00104564
NCT: NCT04314089
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698